“Genome-wide CRISPR screens of multiple pathogenic coronaviruses reveal host factors critical for SARS-CoV-2 infection”

Craig Wilen, MD, PhD
Assistant Professor of Laboratory Medicine and Immunology
Medical Director, Immune Monitoring Core Facility, Yale School of Medicine

Tuesday, October 13, 2020 from 4-4:30 P.M.

https://yale.zoom.us/s/91484905438
Or join by Telephone: 203-432-9666 or 877-853-5247 (Toll Free)
Webinar ID: 914 8490 5438

Host: Dr. Ellen Foxman
Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants. This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will:
1. Have increased understanding of host-determinants of COVID-19 pathogenesis
2. Understand how SARS-CoV-2 establishes infection
3. Understand potential novel host-directed therapeutic targets for SARS-CoV-2

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Craig Wilen: Received consulting fees from Zymo Research Corporation and from Alphasights
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.
SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by
Yale School of Medicine, Human and Translational Immunology Program

“IMPACC: A multisite longitudinal immunophenotyping study of hospitalized COVID-19 patients”

Ruth Montgomery, PhD
Professor of Medicine and Epidemiology (Microbial Diseases); Director, Yale CyTOF Facility
Associate Dean for Scientific Affairs, Yale School of Medicine

Tuesday, October 13, 2020 from 4:30-5 P.M.

https://yale.zoom.us/s/91484905438
Or join by Telephone:  203-432-9666 or 877-853-5247 (Toll Free)
Webinar ID:  914 8490 5438

Host:  Dr. Ellen Foxman
Course Directors:  Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will:
1. Review design and benefits of multicenter translational consortium for COVID-19 research
2. Understand systems immunology approach to characterize disease susceptibility
3. Review multi-omics platforms for immune profiling

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Ruth Montgomery:  None
Carrie Lucas:  None
Ellen Foxman:  None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.